|Ms. Sabrina Martucci Johnson||Pres, CEO, Sec. & Director||N/A||N/A||1967|
|Ms. Lisa Walters-Hoffert||Chief Financial Officer||N/A||N/A||1959|
|Mr. Mark Walters||VP of Operations||N/A||N/A||1955|
|Ms. MarDee J. Haring-Layton||VP of Accounting & Fin.||N/A||N/A||1976|
|Dr. David Friend||Chief Scientific Officer||N/A||N/A||N/A|
Daré Bioscience, Inc., a clinical-stage biopharmaceutical company, focuses on developing and marketing women's reproductive health products in the United States. The company intends to develop therapies in the areas of contraception, vaginal health, sexual health, and fertility. Its product portfolio includes Ovaprene, a non-hormonal monthly contraceptive vaginal ring; Sildenafil Cream, a novel cream formulation of sildenafil to treat female sexual arousal disorder utilizing the active ingredient in Viagra; DARE-BV1, a hydrogel formulation of clindamycin phosphate 2% to treat bacterial vaginosis via a single application; and DARE-HRT1, a combination of bio-identical estradiol and progesterone intravaginal ring for hormone replacement therapy. The company has license agreement with ADVA-Tec, Inc. to develop and commercialize Ovaprene for human contraceptive use; and license and collaboration agreement with Strategic Science and Technologies-D, LLC and Strategic Science Technologies, LLC to develop and commercialize indications for women related to female sexual dysfunction and/or female reproductive health. The company is headquartered in San Diego, California.
Daré Bioscience, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.